Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Lamont

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Anti-Cancer Drugs|August 21, 2007
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancerIan A Cree, Christian M Kurbacher, Alan Lamont, et al.
Anti-Cancer Drugs|August 13, 2002
Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancerFederica Di Nicolantonio, Michael H Neale, Louise A Knight, et al.
Anti-Cancer Drugs|August 19, 2006
The effect of imatinib mesylate (Glivec) on human tumor-derived cellsLouise A Knight, Federica Di Nicolantonio, Pauline A Whitehouse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of CancerFrances A Shepherd, Giuseppe Giaccone, Lesley Seymour, et al.
BMC Cancer|July 5, 2003
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinomaSanjay Sharma, Michael H Neale, Federica Di Nicolantonio, et al.
Lancet (London, England)|October 5, 2010
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialGordon J S Rustin, Maria E L van der Burg, Clare L Griffin, et al.
BMC Cancer|July 20, 2005
Cancer cell adaptation to chemotherapyFederica Di Nicolantonio, Stuart J Mercer, Louise A Knight, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Anti-Cancer Drugs|August 21, 2007
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancerIan A Cree, Christian M Kurbacher, Alan Lamont, et al.
Anti-Cancer Drugs|August 13, 2002
Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancerFederica Di Nicolantonio, Michael H Neale, Louise A Knight, et al.
Anti-Cancer Drugs|August 19, 2006
The effect of imatinib mesylate (Glivec) on human tumor-derived cellsLouise A Knight, Federica Di Nicolantonio, Pauline A Whitehouse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2002
Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of CancerFrances A Shepherd, Giuseppe Giaccone, Lesley Seymour, et al.
BMC Cancer|July 5, 2003
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinomaSanjay Sharma, Michael H Neale, Federica Di Nicolantonio, et al.
Lancet (London, England)|October 5, 2010
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialGordon J S Rustin, Maria E L van der Burg, Clare L Griffin, et al.
BMC Cancer|July 20, 2005
Cancer cell adaptation to chemotherapyFederica Di Nicolantonio, Stuart J Mercer, Louise A Knight, et al.
Pageof 1